[ad_1]
It is estimated that India contributes to about a quarter of all maternal deaths worldwide due to postpartum hemorrhage (PPH), estimating 45,000 maternal deaths during childbirth every year. In order to reduce the mortality rate, the Swiss company Ferring Pharmaceutical has designed a thermostable carbetocin that is as effective as oxytocin, the gold standard treatment for preventing excessive bleeding during childbirth.
The effective spread of thermostable carbetocin will ensure the prevention of HPP-related deaths in India due to its easy storage at high temperatures, which is usually difficult with normal oxytocin. The results of the CHAMPION clinical trial, conducted by WHO in collaboration with Ferring and MSD for mothers, were published in the New England Journal of Medicine (NEJM), a release posted today.
"This is one of these results paves the way for heat-stable carbetocin to potentially save the lives of thousands of women, especially in areas where cold chain transport and storage are not feasible" said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals was quoted in the publication. "We will now work with the WHO and MSD so that mothers can manufacture thermostable carbetocin in the countries where it is most needed, protecting women and families around the world," he said. showed a degradation and a loss of efficacy of oxytocin.
Thermostable carbetocin can save thousands of lives in low- and middle-income countries, where 99% of HPP-related deaths occur and where CHAMPION (Carbetocin Haemorhage Prevention) refrigeration, testing Clinical most important in the prevention of HPP, was a double-blind, randomized, non-inferiority trial designed to compare the efficacy and safety of drugs. experimental thermostable carbetocin to oxytocin in the prevention of HPP after badl delivery. The trial, conducted by the WHO Department of Reproductive Health and Research, including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Program for Research, Development and Research Training, recruited nearly 30 000 women in ten countries, including Argentina, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the United Kingdom. Thermostable carbetocin was studied and developed by Ferring Pharmaceuticals and the CHAMPION study was funded by MSD for Mothers.
Ferring has been developing treatments for mothers and babies for over 50 years. Founded in 1950, the private company Ferring now employs around 6,500 people worldwide, has its own subsidiaries in nearly 60 countries and markets its products in 110 countries, according to the statement.
UNI PL
– (UNI) – – C-1-1-DL0211-1422983.Xml
[ad_2]
Source link
